Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2
2(40.0%)
Phase 1
2(40.0%)
Phase 3
1(20.0%)
5Total
Phase 2(2)
Phase 1(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06709014Phase 3Recruiting

A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

Role: collaborator

NCT05025605Phase 1Recruiting

Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder

Role: collaborator

NCT06652100Active Not Recruiting

Establishment of ProNephro AKI (NGAL) Cut Off Value for Risk Assessment of Moderate to Severe Acute Kidney Injury in Adults

Role: collaborator

NCT04846036Phase 2Suspended

The KHENERGYC Study

Role: collaborator

NCT04604548Phase 2Completed

The KHENEREXT Study

Role: collaborator

NCT04664738Phase 1Unknown

PEP on a Skin Graft Donor Site Wound

Role: collaborator

All 6 trials loaded